Stock Price Quote

POLY MEDICURE LTD.

NSE : POLYMEDBSE : 531768ISIN CODE : INE205C01021Industry : Medical Equipment/Supplies/AccessoriesHouse : Private
BSE1871.85-14.25 (-0.76 %)
PREV CLOSE ( ) 1886.10
OPEN PRICE ( ) 1886.60
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 1791
TODAY'S LOW / HIGH ( )1867.65 1888.80
52 WK LOW / HIGH ( )1822.65 2936.7
NSE1873.70-16.1 (-0.85 %)
PREV CLOSE( ) 1889.80
OPEN PRICE ( ) 1894.90
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 1873.70 (63)
VOLUME 22874
TODAY'S LOW / HIGH( ) 1868.00 1894.90
52 WK LOW / HIGH ( )1821.2 2937.6
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 30-03 1995
Management Info
Devendra Mehta - Chairman Himanshu Baid - Managing Director
Registered Office

Address 232- B, 3rd Floor,Okhla Industrial Estate,Phase I I I,
New Delhi,
Delhi-110020

Phone 011 - 33550700 / 47317000 / 26321838, 81, 89, 93

Email info@polymedicure.com

Website www.polymedicure.com

Registrars Details
MAS Services Ltd
T-34 , 2nd Floor,Okhla Industrial Area,Phase - II,New Delhi
Listing : BSE, NSE

NEWS

14Nov Poly Medicure informs about analyst meet
Poly Medicure has informed that it submitted Transcript of the investor..
24Sep Poly Medicure acquires 90% stake in Pe
Poly Medicure’s wholly owned step-down subsidiary -- RisoR Holdings B.V...
24Sep Poly Medicure rises on acquiring 90% s
Poly Medicure is currently trading at Rs. 1966.80, up by 16.80 points or..
05Sep Poly Medicure informs about conference
Pursuant to the provisions of Regulation 30 and 46(2) (oa) of the Securi..
04Sep Poly Medicure gets nod to acquire Pend
Poly Medicure has received approval to acquire Pendracare Holdings B.V...

Financials

in Millions
QTR Sep 25 ANNUAL 25
Net Profit890.53313.34
Gross Profit 1180.06 4428.9
Operating Profit 1449.45351.36
Net Sales 4165.4216018

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

3B Blackbio Dx (BSE)
peergroup  1418.00 (2.79%)
M.Cap ( in Cr)1217.02
Hemant Surgical Inds (BSE)
peergroup  303.70 (5.00%)
M.Cap ( in Cr)395.98
Amkay Products (BSE)
peergroup  68.28 (20.00%)
M.Cap ( in Cr)59.10
Prevest Denpro (BSE)
peergroup  480.00 (2.14%)
M.Cap ( in Cr)576.14
GKB Ophthalmics (BSE)
peergroup  50.58 (0.26%)
M.Cap ( in Cr)25.50

Shareholding Pattern

MUTUAL FUNDS/UTI 8.04%
PROMOTERS 62.42%
FI/BANKS/INSURANCE 2.83%
NON-INSTITUTION 14.27%
GOVERNMENT 0%
FII 0%

About Poly Medicure Ltd.

Poly Medicure Ltd. was incorporated in the year 1995. Its today's share price is 1871.85. Its current market capitalisation stands at Rs 18972.98 Cr. In the latest quarter, company has reported Gross Sales of Rs. 16091.14 Cr and Total Income of Rs.16915.72 Cr. The company's management includes Ravi Prakash, Avinash Chandra, Pankaj Kumar Gupta, Sonal Mattoo, Amit Khosla, Alessandro Balboni, Vimal Bhandari, Vishal Gupta, Rishi Baid, Himanshu Baid, Ambrish Mithal, Vishal Baid, Jugal Kishore Baid, Devendra Mehta.

It is listed on the BSE with a BSE Code of 531768 , NSE with an NSE Symbol of POLYMED and ISIN of INE205C01021. It's Registered office is at 232- B, 3rd Floor,Okhla Industrial Estate,Phase I I INew Delhi-110020, Delhi. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Doogar & Associates, MC Bhandari & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.